Estrogen and PARP inhibitor combination for advanced ER+ breast cancer shows promise in preclinical models

Advanced estrogen receptor-positive (ER+) breast cancer can be especially difficult to treat. A new study by researchers at Dartmouth Cancer Center led by Todd W. Miller, Ph.D., shows promise in using a combination of estrogen and a PARP inhibitor (a drug that suppresses DNA damage repair), to treat this type of cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *